TriangleNCT02526017 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- other Details
- The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- Inclusion of multiple tumor types and several dose levels in monotherapy and combination with nivolumab limits the ability to accurately evaluate the incidence of off-target effects adverse events.
- point Of Contact
- helen.collins@fiveprime.com
- organization
- Five Prime Therapeutics
- phone
- 650-745-9633
- title
- Helen Collins, Chief Medical Officer
Complete source fields
- certain Agreement
- other Details
- The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation.
- pi Sponsor Employee
- false
- restriction Type
- OTHER
- restrictive Agreement
- true
- limitations And Caveats
- description
- Inclusion of multiple tumor types and several dose levels in monotherapy and combination with nivolumab limits the ability to accurately evaluate the incidence of off-target effects adverse events.
- point Of Contact
- helen.collins@fiveprime.com
- organization
- Five Prime Therapeutics
- phone
- 650-745-9633
- title
- Helen Collins, Chief Medical Officer
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice